Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 16Active not recruiting 7Suspended 3Not yet recruiting 3Withdrawn 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Carcinoma, Merkel Cell 1

Interventions

Specimen Handling 64Magnetic Resonance Spectroscopy 44Carboplatin 34Cyclophosphamide 31Gemcitabine 29Biopsy 28Cisplatin 27Radiotherapy 26pembrolizumab 25Bevacizumab 25Paclitaxel 23Standard of Care 22Oxaliplatin 22Drug Therapy 22venetoclax 21Nivolumab 21Capecitabine 21fludarabine 20Injections 20Interviews as Topic 18Radiosurgery 16Dexamethasone 16Blood Specimen Collection 16Azacitidine 16toripalimab 15tislelizumab 14cemiplimab 13anlotinib 13Irinotecan 13Pemetrexed 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × decitabine and cedazuridine drug combination × 90 days × Clear all
NCT07472322 2026-05-29

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

University of Wisconsin, Madison

Phase 1/2 Not yet recruiting
31 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT07153497 2026-05-13

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
132 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07437950 2026-05-13

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
126 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡